Velazquez, E. J., Ambrosy, A., Morrow, D. A., McCague, K., Duffy, C. I., O’Brien, T. X., … Braunwald, E. (2019). Sacubitril/Valsartan Initiated in Black Patients Admitted for Acute Decompensated Heart Failure Reduced NT-proBNP, was Safe and Led to Improved Clinical Outcomes- A Secondary Analysis of the PIONEER-HF Trial. In Journal of Cardiac Failure (Vol. 25, pp. S80–S80). Elsevier BV. https://doi.org/10.1016/j.cardfail.2019.07.227

Velazquez, Eric J., Andrew Ambrosy, David A. Morrow, Kevin McCague, Carol I. Duffy, Terrence X. O’Brien, Ricardo Rocha, Adam D. DeVore, and Eugene Braunwald. “Sacubitril/Valsartan Initiated in Black Patients Admitted for Acute Decompensated Heart Failure Reduced NT-proBNP, was Safe and Led to Improved Clinical Outcomes- A Secondary Analysis of the PIONEER-HF Trial.” In Journal of Cardiac Failure, 25:S80–S80. Elsevier BV, 2019. https://doi.org/10.1016/j.cardfail.2019.07.227.

Velazquez EJ, Ambrosy A, Morrow DA, McCague K, Duffy CI, O’Brien TX, et al. Sacubitril/Valsartan Initiated in Black Patients Admitted for Acute Decompensated Heart Failure Reduced NT-proBNP, was Safe and Led to Improved Clinical Outcomes- A Secondary Analysis of the PIONEER-HF Trial. In: Journal of Cardiac Failure. Elsevier BV; 2019. p. S80–S80.

Velazquez, Eric J., et al. “Sacubitril/Valsartan Initiated in Black Patients Admitted for Acute Decompensated Heart Failure Reduced NT-proBNP, was Safe and Led to Improved Clinical Outcomes- A Secondary Analysis of the PIONEER-HF Trial.” Journal of Cardiac Failure, vol. 25, no. 8, Elsevier BV, 2019, pp. S80–S80. Crossref, doi:10.1016/j.cardfail.2019.07.227.

Velazquez EJ, Ambrosy A, Morrow DA, McCague K, Duffy CI, O’Brien TX, Rocha R, DeVore AD, Braunwald E. Sacubitril/Valsartan Initiated in Black Patients Admitted for Acute Decompensated Heart Failure Reduced NT-proBNP, was Safe and Led to Improved Clinical Outcomes- A Secondary Analysis of the PIONEER-HF Trial. Journal of Cardiac Failure. Elsevier BV; 2019. p. S80–S80.